For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Vyndamax and Tafamidis meglumine represents a significant breakthrough . These groundbreaking therapies stabilize the transthyretin protein, preventing its damaging build-up and lessening the burden of the disease . Individuals are n